Balaxi Pharmaceuticals Intrinsic Value
Balaxi Pharmaceuticals (BALAXI) median intrinsic value is ₹47.34 from 8 valuation models (range ₹8–₹66), vs current price ₹26.37 — +79.5% upside (Trading Below Calculated Value), margin of safety 44.3%. For current market price and key ratios, visit Balaxi Pharmaceuticals share price today.
BALAXI Valuation Methods Summary — DCF, Graham Number & P/E
Balaxi Pharmaceuticals intrinsic value across 8 models vs current price ₹26.37 — upside/downside and value range per method. Read BALAXI dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹9.68 | ₹7.74 - ₹11.62 | -63.3% | EPS: ₹0.44, Sector P/E: 22x |
| Book Value Method | asset | ₹65.92 | ₹59.33 - ₹72.51 | +150.0% | Book Value/Share: ₹226.36, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹52.74 | ₹47.47 - ₹58.01 | +100.0% | Revenue/Share: ₹269.09, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹52.74 | ₹47.47 - ₹58.01 | +100.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹42.20 | ₹33.76 - ₹50.64 | +60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹7.91 | ₹7.12 - ₹8.70 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹7.91 | ₹7.12 - ₹8.70 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹47.34 | ₹42.61 - ₹52.07 | +79.5% | EPS: ₹0.44, BVPS: ₹226.36 |
BALAXI Intrinsic Value vs Market Price — All Valuation Models
Balaxi Pharmaceuticals fair value range ₹8–₹66 vs current market price ₹26.37 across 8 valuation models. Analyse Balaxi Pharmaceuticals shareholding analysis to track promoter, FII and institutional holdings.
BALAXI Intrinsic Value Analysis — Undervalued or Overvalued?
Balaxi Pharmaceuticals median intrinsic value ₹47.34, current price ₹26.37 — Trading Below Calculated Value by 79.5%, margin of safety 44.3%.
What is the intrinsic value of BALAXI?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Balaxi Pharmaceuticals (BALAXI) is ₹47.34 (median value). With the current market price of ₹26.37, this represents a +79.5% variance from our estimated fair value.
The valuation range spans from ₹7.91 to ₹65.92, indicating ₹7.91 - ₹65.92.
Is BALAXI undervalued or overvalued?
Based on our multi-method analysis, Balaxi Pharmaceuticals (BALAXI) appears to be trading below calculated value by approximately 79.5%.
BALAXI Financial Health — Key Ratios vs Industry Benchmarks
Balaxi Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.65 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 1.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 0.88x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BALAXI Cash Flow Quality — Operating & Free Cash Flow
Balaxi Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-35 Cr | ₹-46 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹5 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹6 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹34 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |